Day: December 2, 2025

THE HAGUE, NETHERLANDS, Dec 2, 2025 - (ACN Newswire via SeaPRwire.com) - As scammers adopt increasingly sophisticated methods powered by artificial intelligence, global coordination and responsible innovation have become essential to protecting consumers. Today, the Global Anti-Scam Alliance (GASA) and OpenAI announce that OpenAI has joined GASA as a Foundation Member, marking a significant step forward in the shared mission to combat AI-enabled fraud and strengthen digital safety worldwide.OpenAI Joins GASAOpenAI is an AI research and deployment company whose mission is to ensure AI benefits all of humanity. The company heavily invests in safety and misuse prevention, including efforts to detect and disrupt malicious attempts to use AI systems for scams, phishing, fraud, and other harms. OpenAI also publicly shares lessons from this work to strengthen collective defenses and reinforce its commitment to transparency and responsible deployment."The rise of AI enabled scams demands coordinated action across technology, policy, and law enforcement. OpenAI's efforts to detect and disrupt malicious use of AI systems align closely with our mission. Their decision to join GASA as a Foundation Member sends a strong signal that protecting consumers in the age of AI requires shared intelligence, shared responsibility, and shared purpose," said Jorij Abraham, Managing Director of GASA."Scams are one of the fastest-growing threats people face online, and our tools are increasingly good at spotting them. That's why OpenAI is joining the Global Anti-Scam Alliance, where we can share insights, strengthen our collective defenses, and help people stay safe. This work fits squarely within our mission to build AI tools that benefit all of humanity," said Will McCants, Head of Intelligence and Investigations at OpenAI.By joining GASA as a Foundation Member, OpenAI will contribute to global research, the global advisory board, and cross-sector collaboration focused on reducing the impact of AI-enabled scams. This partnership strengthens the collective effort to build safer digital ecosystems and ensure that innovation is supported by safeguards, accountability, and shared intelligence.Read the full release here.Contact InformationMetje van der MeerMarketing Directormetje.vandermeer@gasa.orgSOURCE: Global Anti-Scam AllianceRelated Images Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

荷兰海牙, 2025年12月2日 - (亚太商讯 via SeaPRwire.com) - 随着诈骗分子运用人工智能实施日益复杂的犯罪手段，全球协同与负责任的创新已成为保护消费者权益的关键。今日，全球反诈骗联盟（GASA）与OpenAI联合宣布，OpenAI正式加入GASA成为创始成员，标志着双方在打击人工智能驱动欺诈、强化全球数字安全领域取得重大进展。OpenAI加入GASAOpenAI是一家致力于确保人工智能造福全人类的AI研究与部署公司。该公司大力投入安全防护与滥用预防工作，包括侦测并阻断利用AI系统实施诈骗、网络钓鱼、欺诈及其他危害的恶意企图。OpenAI还公开分享相关经验教训，以强化集体防御体系，践行透明化与负责任部署的承诺。“人工智能驱动的诈骗日益猖獗，亟需技术界、政策制定者和执法部门协同行动。OpenAI在侦测和阻断恶意利用人工智能系统方面的努力与我们的使命高度契合。他们决定以创始成员身份加入GASA，有力表明在人工智能时代保护消费者需要共享情报、共同承担责任、凝聚共同目标，”GASA执行董事乔里·亚伯拉罕表示。OpenAI情报与调查主管威尔·麦坎茨表示：“诈骗已成为网络环境中增长最快的威胁之一，而我们的工具正日益精进于识别此类风险。正因如此，OpenAI选择加入全球反诈骗联盟——在此平台上，我们能共享洞见、强化集体防御、守护民众安全。这项工作与我们'构建造福全人类的人工智能工具'的使命高度契合。”作为创始成员加入GASA后，OpenAI将参与全球研究、全球顾问委员会及跨领域协作，共同致力于降低人工智能驱动型诈骗的影响。此次合作强化了构建更安全数字生态系统的集体努力，确保创新在保障措施、问责机制和情报共享的支持下推进。阅读完整新闻稿请点击此处。联系方式梅特杰·范德梅尔市场总监metje.vandermeer@gasa.org 来源：全球反诈骗联盟 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Direct landing of the Nongsa–Changi submarine cable into Digital Realty’s SIN12 facility to boost cross-border network resilience and capacityEnhanced interconnection to enable faster, more reliable data exchange across NDP1 and SIN12 to support rising AI, cloud, and hyperscale workloadsIntegration of BW Digital’s subsea system with PlatformDIGITAL® to accelerate customer access to scalable, high-performance infrastructure SINGAPORE, Dec 2, 2025 - (ACN Newswire via SeaPRwire.com) - Digital Realty, the largest global provider of cloud-and carrier-neutral data centre, colocation, and interconnection solutions, today announced a partnership with BW Digital to strengthen cross-border DC-to-DC connectivity between Singapore and Indonesia.(Left to Right: Johnny Sek, Commercial Sales Manager, Digital Realty; Hamid Maani, Chief Sales Officer, BW Digital; Jo Jo Kwong, Director, Strategy & Business Development, Digital Realty; Serene Nah, Managing Director & Head of Asia Pacific, Digital Realty; Govind Choudhary, General Manager, SEA & India, Digital Realty; Virginie Frouin, Chief Business Office, Connectivity, BW Digital; Florent Blot, Chief Business Officer, Datacenter & Value Added Services, BW Digital; Robert Ho, Director, Market Development, Digital Realty)Under the agreement, the companies will jointly support the rollout of BW Digital’s Nongsa Changi Cable System (NCC), a new submarine system designed to connect Batam in Indonesia with Singapore, also overseeing its integration with Digital Realty’s SIN12 data centre on the Island State.The undertaking is expected to provide access to vital cloud and connectivity hubs, particularly for enterprises expanding across Southeast Asia, strengthening cross-border connectivity, storage and compute, and supporting Singapore’s accelerating AI and digital transformation demands. This is strengthened by SIN12’s ability to support high-performance workloads at scale, giving enterprises confidence as they expand between Singapore and Batam.Southeast Asia’s AI-Driven InfrastructureBy landing NCC in SIN12, BW Digital and Digital Realty hope to deliver faster, more reliable, and more sustainable data exchange between Singapore and Batam, which is emerging as a strategic hub for hyperscale and AI infrastructure.As the first submarine cable to land directly in Nongsa Digital Park, NCC is expected to offer unprecedented resilience to Batam. It is designed to deliver more than 1.6 petabits per second (Pb/s) of new capacity and provide seamless DC-to-DC connectivity with less than 2 milliseconds (ms) latency to Singapore.The collaboration is designed to integrate submarine cable landing facilities with Digital Realty’s global data centre platform, hoping to enable high-performance subsea connectivity, storage and interconnection within SIN12 and Artificial Intelligence/Machine Learning (AI/ML) computing enablement via PlatformDIGITAL.Furthermore, BW Digital’s customers may also be able to expand their connectivity ecosystems and scale AI workloads by establishing interconnections directly within SIN12, while reaping cost efficiencies by enabling seamless cross connects to other providers already hosted in the facility. BW Digital’s in-progress NDP-1 data centre in Batam will further support Digital Realty’s customers with access to colocation and cloud connectivity options in Singapore+ (or SIJORI, the Singapore-Johor-Riau Growth Triangle), one of the region’s fastest-growing digital hubs.This ‘AI Factory’ NDP1 data centre, with a capacity of 144MW and liquid cooling capabilities, is designed to feature direct on-ramps to BW Digital’s subsea cable landing station for low-latency and resilient links to regional markets.At a signing ceremony in Singapore today, Serene Nah, Managing Director and Head of Asia Pacific, Digital Realty, said: “Subsea networks are central to Southeast Asia’s digital economy, and Singapore continues to serve as a critical gateway for regional data exchange. By integrating BW Digital’s Nongsa–Changi system into SIN12, we are working to deliver faster and more resilient connectivity to support customers as they scale next-generation workloads. This collaboration reinforces our commitment to strengthening the interconnection foundation that powers the region’s digital growth”.Virginie Frouin, chief business officer, BW Digital said: “This partnership represents a major milestone for BW Digital, aligning with our mission to support digital transformation by bridging the gap between submarine cable infrastructure and land-based digital platforms in a way that is efficient, secure, and future-ready.”“We are hoping to enable AI workloads, provide reliable, secure connectivity between Singapore and Batam, support for rising demand in cross-border data exchange, and ongoing collaboration with Digital Realty to empower customers with greater interconnection flexibility”.About Digital RealtyDigital Realty brings companies and data together by delivering the full spectrum of data center, colocation and interconnection solutions. PlatformDIGITAL®, the company's global data center platform, provides customers with a secure data meeting place and a proven Pervasive Datacenter Architecture (PDx®) solution methodology for powering innovation, from cloud and digital transformation to emerging technologies like artificial intelligence (AI), and efficiently managing Data Gravity challenges. Digital Realty gives its customers access to the connected data communities that matter to them with a global data center footprint of 300+ facilities in 50+ metros across 25+ countries on six continents. To learn more about Digital Realty, please visit digitalrealty.com or follow us on LinkedIn and X.About BW DigitalHeadquartered in Singapore and part of BW Group, BW Digital develops, builds and operates digital infrastructure in high-potential markets.Our vision is to create a sustainable digital ecosystem for cloud and AI workloads by combining data centres, connectivity and renewable energy.Our main assets include the 15,000km Hawaiki submarine cable connecting Australia, New Zealand and the US since 2018, and the BW Digital Campus at Nongsa Digital Park, comprising the 144MW NDP1 data centre, the NCC submarine cable between Singapore and Batam and the Citra Connect terrestrial fibre network.Media ContactsDavid BinningBrand Comms Bureau (On behalf of BW Digital)David.binning@bcbureau.com.au Safe Harbor StatementThis press release contains forward-looking statements which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially, including statements related to the APAC market, development plans in APAC, the company's strategy, expected growth in digital transformation, and customer demand. For a list and description of such risks and uncertainties, see the reports and other filings by the company with the U.S. Securities and Exchange Commission. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ANKARA, Turkey, Dec 2, 2025 - (ACN Newswire via SeaPRwire.com) - GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, has announced new positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class, novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) in San Diego, CA (United States) today.SUL-238 was originally discovered by Sulfateq and has since been further developed through a collaborative effort of Sulfateq and GEN as a novel therapeutic in neurodegenerative diseases.This Phase 1 randomized, double-blind, placebo-controlled study evaluated the safety, tolerability, and pharmacokinetics (PK) after multiple-ascending doses (MAD) of orally administered SUL-238 in healthy elderly men and women (aged ≥40 years). The study included two cohorts with a treatment period of 14 days and a safety follow-up through 14 days after the last dose. 15 healthy adults in each cohort were randomized in a 2:1 ratio to receive SUL-238 or placebo. Total daily dose of SUL-238 was 4000 mg (2000 mg b.i.d., first cohort) or 4500 mg (1500 mg t.i.d., second cohort). SUL-238 demonstrated an excellent safety and tolerability profile after multiple doses in both cohorts, while demonstrating a favourable PK profile and a high cerebrospinal fluid (CSF) penetration, making it a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.Key Findings:Safety in both cohorts:No clinically significant changes were observed in physical and neurological exams, vital signs, ECG, and clinical laboratory parameters.AE rates were comparable between participants receiving SUL-238 and placebo.All AEs were of mild intensity or considered not related to SUL-238.First cohort PK (2000 mg b.i.d.):SUL-238 was rapidly absorbed with a mean time to maximum plasma concentration (Tmax) reached at 1.25(±0.54) and 1.50(±0.53) hours on day 1 and day 14, respectively.Mean terminal elimination half-life (t1/2) was3.50(±1.06) hours on day 14.Mean trough plasma concentration of SUL-238 was 39.23(±24.31) ng/mL and 41.49(±18.20) ng/mL on day 8 and day 14, respectively.Second cohort PK (1500 mg t.i.d.):SUL-238 was rapidly absorbed, with a mean time to maximum plasma concentration (Tmax) reached at 0.95(±0.16) and 1.00(±0.00) hours on day 1 and day 14, respectively.Mean terminal elimination half-life (t1/2):3.74(±1.84) hours on day 14.Mean trough plasma concentration of SUL-238 was 57.98(±31.08) and 60.63(±64.14) ng/mL on day 8 and day 14, respectively.Abidin Gülmüş, Chairman of GEN, stated:"We're greatly motivated by these new positive results of SUL-238 in our Phase 1 trial, which mark a key advance toward addressing Alzheimer's disease at its biological foundation."Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added:"With its excellent safety and PK profile in this Multiple Ascending Dose Phase 1 trial, SUL-238 continues to represent a very strong drug candidate for further clinical development aimed at meeting the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease.About SUL-238SUL-238 is a novel, first-in-class, hibernation-derived small molecule designed to target mitochondria, the 'powerhouse' of the cell. SUL-238 supports mitochondrial bioenergetics via complex I/IV activation and enhances mitochondrial function in various preclinical models for neurodegenerative, cardiovascular, and renal diseases, as well as in accelerated aging. SUL-238 exhibits the capability to cross the blood-brain barrier and has undergone extensive safety evaluation in preclinical and clinical Phase 1 studies. GEN licenses SUL-238 from Sulfateq B.V. for neurodegenerative disease applications.About GEN:Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. Through significant R&D investments and global collaborations, GEN is committed to advancing healthcare worldwide. The company develops and manufactures high-quality, competitive products at its GMP-certified production facility and continues its bold efforts in original drug development via two dedicated R&D centers.About Sulfateq:Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centres to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health.For more information:www.genilac.com.trwww.sulfateqbv.comContact InformationBulutay GüneşSr. Head of Corporate Brandb.gunes@genilac.comFatih GörenInvestor Relations Managerf.goren@genilac.comSOURCE: GEN İlaç ve Sağlık Ürünleri A.Ş. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

安卡拉，土耳其, 2025年12月2日 - (亚太商讯 via SeaPRwire.com) - 土耳其领先的专科制药公司GEN Pharmaceuticals（GENIL.IS）宣布，其针对首创口服线粒体靶向药物候选物 SUL-238 的安全性、耐受性和药代动力学（PK）的 I 期临床试验在健康老年志愿者中取得新的积极结果。该研究成果于今日在美国加利福尼亚州圣地亚哥举行的第 18 届阿尔茨海默病临床试验大会（CTAD）上公布。SUL-238 最初由 Sulfateq 公司发现，随后通过 Sulfateq 与 GEN 的合作研发，成为治疗神经退行性疾病的新型药物。这项 I 期随机、双盲、安慰剂对照研究评估了健康老年男性和女性（≥40 岁）口服 SUL-238 进行多次递增剂量（MAD）后的安全性、耐受性和药代动力学（PK）。研究包含两个队列，治疗期为 14 天，并在最后一次给药后进行为期 14 天的安全性随访。每个队列的 15 名健康成人按 2:1 比例随机分配接受 SUL-238 或安慰剂。SUL-238 每日总剂量为4000 mg（首组：2000 mg，每日两次）或 4500 mg（次组：1500 mg，每日三次）。在两组受试者中，SUL-238 经多次给药后均表现出优异的安全性和耐受性，同时具有良好的药代动力学特征和高脑脊液（CSF）渗透性，使其成为阿尔茨海默病和帕金森病等神经退行性疾病进一步临床开发的潜在候选药物。主要发现：两组安全性：体格检查、神经系统检查、生命体征、心电图及临床实验室参数均未见临床显著变化。SUL-238 组与安慰剂组不良事件发生率相当。所有不良事件均为轻度或与 SUL-238 无关。第一组药代动力学（2000 mg b.i.d.）：SUL-238 吸收迅速，第 1 天和第 14 天达到血浆峰浓度（Tmax）的平均时间分别为 1.25(±0.54)小时和 1.50(±0.53)小时。第 14 天平均终末消除半衰期(t1/2)为 3.50(±1.06)小时。第 8 天和第 14 天 SUL-238 平均谷浓度分别为 39.23(±24.31) ng/mL 和41.49(±18.20) ng/mL。第二组药代动力学（1500 mg t.i.d.）：SUL-238 吸收迅速，平均血浆峰浓度达峰时间（Tmax）分别为第 1 天 0.95(±0.16)小时和第 14 天 1.00(±0.00)小时。第 14 天平均终末消除半衰期(t1/2)：3.74(±1.84)小时。第 8 天和第 14 天 SUL-238 平均谷浓度分别为 57.98(±31.08)和 60.63(±64.14)ng/mLGEN 董事长 Abidin Gülmüş 表示：“SUL-238 在 I 期临床试验中取得的新成果令人振奋，这标志着我们朝着从生物学根源治疗阿尔茨海默病迈出了关键 ”一步。GEN 研发副总裁 Nadir Ulu 医学博士补充道：“在本次多剂量递增 I 期试验中，SUL-238 展现出卓越的安全性和药代动力学特征，继续成为极具潜力的候选药物，有望满足包括阿尔茨海默病在内的神经退行性疾病领域亟待解决的关键 ”需求。关于 SUL-238SUL-238 是一种创新的首创冬眠衍生物小分子药物，旨在靶向细 “ ”——胞的 能量工厂 线粒体。该药物通过激活复合物 I/IV 支持线粒体生物能代谢，并在多种神经退行性疾病、心血管疾病、肾脏疾病及加速衰老的临床前模型中增强线粒体功能。SUL-238 具有穿透血脑屏障的能力，已在临床前和临床 I 期研究中经过全面的安全性评估。GEN 从 Sulfateq B.V.获得 SUL-238 的神经退行性疾病应用许可。关于 GEN：GEN 成立于 1998 年，是土耳其领先的专科制药企业，专注于多个治疗领域的创新疗法研发。通过重大研发投入和全球合作，GEN 致力于推动全球医疗健康事业发展。公司在GMP 认证的生产基地开发制造高品质、具竞争力的产品，并通过两个专业研发中心持续推进原创药物研发工作。关于 Sulfateq：Sulfateq B.V.是一家荷兰早期生物技术公司，致力于与学术及工业研究机构建立战略合作，加速创新药物的研发进程。该公司开发了一类新型小分子化合物——SUL 化合物，可维持线粒体健康。更多信息：www.genilac.com.trwww.sulfateqbv.com 联系方式Bulutay Güneş企业品牌高级主管b.gunes@genilac.comFatih Gören投资者关系经理f.goren@genilac.com来源：GEN 制药与健康产品股份有限公司 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Partnership drives clinical research, hands-on student training, and access to cutting-edge medical technologiesPETALING JAYA, Malaysia, Dec 2, 2025 - (JCN Newswire via SeaPRwire.com) - AdipoLABs Co., Ltd. and Red & Blue Co., Ltd. from Korea, together with their Malaysian subsidiary, AdipoLABs Healthcare (M) Sdn Bhd, today officially opened the new AdipoLABs regional office for Asia-Pacific, marking a strategic expansion to strengthen its leadership in non- invasive healthcare and build a robust MedTech ecosystem in Malaysia and across ASEAN.As a research and development-focused medical company, its presence is expected to drive knowledge transfer, foster R&D collaboration, provide industry-standard training, and enhance the country’s preventive healthcare capabilities. Tocommemorate this milestone, the company also signed two Memoranda of Understanding (MoUs) with the University of Cyberjaya (UoC), formalising a partnership to advance healthcare innovation, clinical research, and talent development.“By uniting our hyperthermia technology with local expertise and academic rigour, we’ll expedite the adoption of advanced solutions and improve patient outcomes worldwide. We envision this collaboration as a blueprint for international healthcare partnerships,” said Mr. Han Sung-ho, CEO of AdipoLABs Co., Ltd.A cornerstone of the first MoU is a comprehensive internship programme with UoC’s Physiotherapy programmes under the Faculty of Health, offering six-month placements and potential job opportunities to give students invaluable real-world experience. Students from the Faculty of Health will gain hands-on expertise with AdipoLABs’ Pain Bot device, enhancingtheir skills in pain detection and treatment, while students from the School of Biomedical Engineering will support AdipoLABs’ technical operations, strengthening after-sales service and device maintenance.As part of the partnership, AdipoLABs will implement a strategic client engagement initiative, where interns may be placed at client facilities to demonstrate device effectiveness and provide on-site support. This initiative highlights the interns’ value, encourages potential permanent employment, and ensures optimal use of the technology. The collaboration also extends to clinical research, with UoC professors and students conducting studies on various AdipoLABs medical devices, generating evidence-based insights to be published in reputable journals and scientifically validating the technologies.“We’re thrilled to collaborate with the University of Cyberjaya to cultivate local talent and drive Malaysian healthcareinnovation. This partnership offers UoC students invaluable hands-on experience with technologies like Pain Bot. It also expands our clinical research, enhancing pain management solutions for patients across Malaysia and ASEAN. We are dedicated to empowering future healthcare leaders,” said Dr. Isaac R. Joseph, Director of AdipoLABs Healthcare (M) Sdn Bhd.In a parallel effort to advance physiotherapy education, AdipoLABs Malaysia, Red & Blue Co., Ltd., and UoC signed a second MoU focused on knowledge transfer and medical device donation. Under this agreement, AdipoLABs Malaysia willdonate a Pain Bot unit to UoC, giving students access to cutting-edge pain detection and treatment technology and enhancing their knowledge and skills in innovative musculoskeletal pain management methods.AdipoLABs, a Ministry of Health (MOH)-registered medical-device establishment under the Medical Device Authority(MDA), anchors this collaboration with proven regulatory credibility and a strong commitment to quality and innovation. Their certified standing reinforces UoC’s ambition to accelerate evidence-based research and industry-ready healthcare solutions.“AdipoLABs’ partnership with the University of Cyberjaya is more than a collaboration, it is a direct investment in the next generation of healthcare professionals. With the introduction of advanced rehabilitative technologies, our students gain access to international-standard tools and real-world innovation that will shape their confidence, competence, and future careers,” said Professor Dr. David Whitford, Vice-Chancellor of the University of Cyberjaya.Further strengthening this collaboration, Professor Dr. Yoo Seung-mo from South Korea, the inventor of the Pain Bot, will serve as an Adjunct Professor at UoC. Dr. Yoo will provide on-site training and ongoing remote mentorship, ensuringstudents receive the highest level of expertise in utilising the Pain Bot technology and applying advanced pain detection and treatment techniques.Together, UoC and AdipoLABs are positioned to drive forward Malaysia’s healthcare innovation agenda with greater confidence and impact.For more information on University of Cyberjaya or AdipoLABs Healthcare (M) Sdn Bhd, kindly visit: University of Cyberjaya – Premier University in Malaysia or adipolabs-msia.com – AdipoLABs Healthcare MalaysiaABOUT UNIVERSITY OF CYBERJAYA (UOC)The University of Cyberjaya is a premier institution located in Malaysia's first smart city, offering a transformative educational experience on a state-of-the-art, eco-friendly campus. The University was recently ranked in the top 1,000 universities in the world under the QSWorld University Rankings and is also currently ranked top 450 under the QS Asia University Rankings 2026.The University is renowned for its excellence in medicine, teaching, employability, facilities, and social responsibility. Additionally, itholds a Top 601+ ranking in the Times Higher Education Sustainability Impact Rankings, excelling in Top 200 for Good Health and Well-being (SDG 3).Founded in 2005 with a focus on medicine and pharmacy, the University has expanded to offer over 50 programmes across diverse fields such as medicine, health sciences, nursing, pharmaceutical sciences, psychology, business, and biomedical engineering. With a globalcommunity of over 10,000 students and over 13,000 alumni, the University is shaping future leaders who are making significant contributions to various industries. The University’ impact is reflected in its graduates, who have contributed to innovations in healthcareduring the COVID-19 pandemic, participated in international humanitarian missions, and made significant advancements across industries such as business and biomedical engineering.The University is guided by Chancellor Tan Sri Dato' Seri Dr. Noor Hisham Abdullah, a prominent figure in global healthcarefor World Health Organization (WHO) initiatives and former Director-General of the Malaysian Ministry of Health. Chairman Professor Tan Sri Dato' Dr. Mohd Amin Jalaludin, former Vice-Chancellor of the University of Malaya, provides strategic governance as Chairman of the Board of Governors. Under the leadership of Vice Chancellor Professor Dr. David Whitford, the University is strengthening itsglobal outlook and academic excellence. The university can be contacted at +603 8313 7000.About AdipoLABs Co., Ltd.AdipoLABs Co., Ltd. is a South Korean medical device company specialising in innovative hyperthermia cancer treatment technology. The company is the manufacturer of the Remission 1℃, a high-frequency hyperthermia device used in hospitals worldwide as an adjunct therapy for cancer treatment. With a commitment to research and development, AdipoLABs strives to improve patient outcomes andcontribute to a future free from the burden of disease. AdipoLABs has a global presence, with branches in India, China, and Malaysia.About AdipoLABs Healthcare (M) Sdn BhdAdipoLABs Healthcare (M) Sdn Bhd, established in Malaysia in 2018, is a subsidiary of AdipoLABs Co., Ltd. As the sole distributor of AdipoLABs medical devices in Malaysia and authorised representative for sales, marketing, and after-sales service throughout the ASEAN region, the company is committed to bringing innovative, non-invasive medical devices and innovative solutions to the Southeast Asian market. The company works closely with an international team of researchers, doctors, lab technicians, and engineers toprovide cutting-edge healthcare technology to the ASEAN market. Dr. Isaac R. Joseph and Mr. Moses Balagopal are the Directors and Co-founders of AdipoLABs Healthcare (M) Sdn Bhd.About Red & Blue Co., Ltd.Red & Blue Co., Ltd. is a South Korean company specialising in the development and distribution of advanced medical devices andhealthcare solutions. As a key partner of AdipoLABs Co., Ltd., Red & Blue Co., Ltd. is committed to supporting education and traininginitiatives that promote the effective use of innovative pain detection and pain treatment techniques. Dr. Yoo works closely with healthcare professionals and academic institutions to advance the field of pain management and improve patient outcomes.Issued by MNAIR PR Consultancy Sdn Bhd on behalf of University of Cyberjaya and AdipoLABs Healthcare (M) Sdn Bhd Contacts for Media Enquiries:MNAIR PR Consultancy Sdn Bhd Ameera HaniAssociate Director, Public Relations+6014 2243296ameera@mnairpr.comUniversity of Cyberjaya (UoC) Ehya NadzeriCommunicationsCyberjaya Education Group Berhad gcmc@cyberjaya.edu.my Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年12月2日 - (亚太商訊) - 试验数据再次验证，HTD1801靶向2型糖尿病发生及发展的根源性问题，实现更全面的心血管代谢综合获益。君圣泰医药（股票代码：2511.HK），一家专注于开发多功能创新疗法，以解决代谢性慢病未满足临床需求的创新药公司，宣布HTD1801在2型糖尿病（T2DM）患者中开展的与达格列净头对头的临床III期试验（HARMONY）取得了积极的结果，试验达到主要终点，并在多项关键心血管代谢指标的改善上优于达格列净。HARMONY（NCT06415773）是一项随机、双盲、阳性药物对照的III期临床研究（N=369），旨在评估HTD1801与达格列净相比，在二甲双胍治疗后血糖控制不佳的成年T2DM患者中的有效性与安全性。研究的主要终点为：治疗24周后HbA1c相对于基线的变化（非劣效界值为0.4%）。次要终点包括多项心血管代谢指标。- 达成主要终点：HTD1801治疗24周后，HbA1c的最小二乘（LS）均值变化为-1.12%，达格列净组为-0.93%（LS均值差异：-0.20%；95% CI：-0.37 ~ -0.03；P < 0.001）。- 达成多项次要终点：相较达格列净，HTD1801在LDL-C与non-HDL-C降低方面明显更优，需要新增或强化他汀类治疗的患者比例也显著低于达格列净组。HTD1801还在多个心血管代谢指标的改善上优于达格列净，如治疗后有更高比例的患者达到HbA1c